Literature DB >> 30605222

Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review.

Aaron P Mitchell1, Jason S Rotter2, Esita Patel3, Daniel Richardson3,4,5, Stephanie B Wheeler2,3,5, Ethan Basch2,4,5, Daniel A Goldstein2,6.   

Abstract

IMPORTANCE: Significant controversy exists regarding whether physicians factor personal financial considerations into their clinical decision making. Within oncology, several reimbursement policies may incentivize physicians to increase health care use.
OBJECTIVE: To evaluate whether the financial incentives presented by oncology reimbursement policies affect physician practice patterns. EVIDENCE REVIEW: Studies evaluating an association between reimbursement incentives and changes in reimbursement policy on oncology care delivery were reviewed. Articles were identified systematically by searching PubMed/MEDLINE, Web of Science, Proquest Health Management, Econlit, and Business Source Premier. English-language articles focused on the US health care system that made empirical estimates of the association between a measurement of physician reimbursement/compensation and a measurement of delivery of cancer treatment services were included. The Risk of Bias in Non-Randomized Studies of Interventions tool was used to assess risk of bias. There were no date restrictions on the publications, and literature searches were finalized on February 14, 2018.
FINDINGS: Eighteen studies were included. All were observational cohort studies, and most had a moderate risk of bias. Heterogeneity of reimbursement policies and outcomes precluded meta-analysis; therefore, a qualitative synthesis was performed. Most studies (15 of 18 [83%]) reported an association between reimbursement and care delivery consistent with physician responsiveness to financial incentives, although such an association was not identified in all studies. Findings consistently suggested that self-referral arrangements may increase use of radiotherapy and that profitability of systemic anticancer agents may affect physicians' choice of drug. Findings were less conclusive as to whether profitability of systemic anticancer therapy affects the decision of whether to use any systemic therapy. CONCLUSIONS AND RELEVANCE: To date, this study is the first systematic review of reimbursement policy and clinical care delivery in oncology. The findings suggest that some oncologists may, in certain circumstances, alter treatment recommendations based on personal revenue considerations. An implication of this finding is that value-based reimbursement policies may be a useful tool to better align physician incentives with patient need and increase the value of oncology care.

Entities:  

Mesh:

Year:  2019        PMID: 30605222     DOI: 10.1001/jamaoncol.2018.6196

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  10 in total

1.  Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice.

Authors:  Aaron P Mitchell; Alan C Kinlaw; Sharon Peacock-Hinton; Stacie B Dusetzina; Hanna K Sanoff; Jennifer L Lund
Journal:  Oncologist       Date:  2019-10-14

Review 2.  Review of Current Policy Strategies to Reduce US Cancer Drug Costs.

Authors:  Angela K Green; Jennifer A Ohn; Peter B Bach
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

Review 3.  Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.

Authors:  Douglas Grossman; Nwanneka Okwundu; Edmund K Bartlett; Michael A Marchetti; Megan Othus; Daniel G Coit; Rebecca I Hartman; Sancy A Leachman; Elizabeth G Berry; Larissa Korde; Sandra J Lee; Menashe Bar-Eli; Marianne Berwick; Tawnya Bowles; Elizabeth I Buchbinder; Elizabeth M Burton; Emily Y Chu; Clara Curiel-Lewandrowski; Julia A Curtis; Adil Daud; Dekker C Deacon; Laura K Ferris; Jeffrey E Gershenwald; Kenneth F Grossmann; Siwen Hu-Lieskovan; John Hyngstrom; Joanne M Jeter; Robert L Judson-Torres; Kari L Kendra; Caroline C Kim; John M Kirkwood; David H Lawson; Philip D Leming; Georgina V Long; Ashfaq A Marghoob; Janice M Mehnert; Michael E Ming; Kelly C Nelson; David Polsky; Richard A Scolyer; Eric A Smith; Vernon K Sondak; Mitchell S Stark; Jennifer A Stein; John A Thompson; John F Thompson; Suraj S Venna; Maria L Wei; Susan M Swetter
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

Review 4.  Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.

Authors:  Scott F Huntington
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Aaron P Mitchell; Akriti Mishra Meza; Katherine S Panageas; Allison Lipitz-Snyderman; Peter B Bach; Michael J Morris
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

Review 6.  TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

Authors:  Ashkan Shahbandi; Hoang D Nguyen; James G Jackson
Journal:  Trends Cancer       Date:  2020-02-05

7.  Conflicts of interest in dialysis: A barrier to policy reforms.

Authors:  Aaron Glickman; Eugene Lin; Jeffrey S Berns
Journal:  Semin Dial       Date:  2020-01-03       Impact factor: 3.455

8.  Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.

Authors:  Lorraine T Dean; Marshalee George; Kimberley T Lee; Kimlin Ashing
Journal:  Cancer       Date:  2020-05-21       Impact factor: 6.860

9.  Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies.

Authors:  Christopher R Manz; Angela C Tramontano; Hajime Uno; Ravi B Parikh; Justin E Bekelman; Deborah Schrag
Journal:  JAMA Netw Open       Date:  2022-09-01

10.  Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand.

Authors:  David I Pryor; Jarad M Martin; Jeremy L Millar; Heather Day; Wee Loon Ong; Marketa Skala; Liesel M FitzGerald; Benjamin Hindson; Braden Higgs; Michael E O'Callaghan; Farhan Syed; Amy J Hayden; Sandra L Turner; Nathan Papa
Journal:  JAMA Netw Open       Date:  2021-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.